Cumberland Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$7.2M
Doctors Paid
11,769
Transactions
33,535
2024 Total
$867,641
Payment Breakdown by Category
Research$4.6M (63.2%)
Consulting$1.2M (17.1%)
Food & Beverage$673,240 (9.3%)
Travel$65,035 (0.9%)
Royalty/License$55,508 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 560 | 63.2% |
| Consulting Fee | $1.2M | 256 | 17.1% |
| Food and Beverage | $673,240 | 31,628 | 9.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $510,144 | 385 | 7.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $108,828 | 64 | 1.5% |
| Travel and Lodging | $65,035 | 177 | 0.9% |
| Royalty or License | $55,508 | 14 | 0.8% |
| Education | $3,131 | 448 | 0.0% |
| Grant | $2,800 | 1 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,000 | 1 | 0.0% |
| Entertainment | $158.50 | 1 | 0.0% |
Payments by Type
Research
$4.6M
559 transactions
General
$2.7M
32,975 transactions
Ownership
$0
1 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| CPI-IFE-005 | $930,467 | 0 | 50 |
| ORAL IFETROBAN IN SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) | $797,378 | 0 | 92 |
| ORAL IFETROBAN TO TREAT DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (SSC) OR SSC-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION | $372,063 | 0 | 93 |
| CPI-IFE-004 | $367,688 | 0 | 29 |
| Milrinone (127) | $357,857 | 0 | 22 |
| FR44 | $336,810 | 0 | 12 |
| ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | $226,267 | 0 | 24 |
| CPI-CL-022 | $215,632 | 0 | 25 |
| R41DK106779 | $130,028 | 0 | 7 |
| ORAL IFETROBAN TO TREAT ASPIRIN EXACERBATED RESPIRATORY DISEASE (AERD) | $103,847 | 0 | 43 |
| CPI-IFE-006 | $92,765 | 0 | 22 |
| AERD Study - 22676 | $66,168 | 0 | 8 |
| Kuti IIT | $60,500 | 0 | 1 |
| aSAH NAC Trial | $51,458 | 0 | 1 |
| Protocol 0101 | $44,242 | 0 | 15 |
| CPI-CL-021 | $40,000 | 0 | 1 |
| Protocol: 0101 | $29,000 | 0 | 12 |
| TELAVANCIN PEDIATRIC PK STUDY (AGES >3 MONTHS TO 17 YEARS) | $25,899 | 0 | 5 |
| Omeclamox Efficacy | $25,000 | 1 | 1 |
| ResearchProtocol 0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy Nov 23, 2018 | $22,582 | 0 | 4 |
| ResearchProtocol 0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy Nov 28, 2018 | $21,435 | 0 | 2 |
| CPI-IFE -004 SSc | $19,904 | 0 | 2 |
| CPI-IFE -SSc | $17,252 | 0 | 1 |
| ResearchProtocol 0112 Dec 07, 2018 | $15,016 | 0 | 3 |
| THROMBOXANE RECEPTOR ANTAGONIST TO IMPROVE ENDOTHELIAL CELL FUNCTION (TRAP) | $15,000 | 0 | 1 |
| IRB Review | $13,287 | 0 | 1 |
| IFE-MTA | $12,643 | 0 | 1 |
| ResearchPharmacokinetics and Tolerability of TLVN at Differing Dosing Regimens in Cystic Fibrosis Adults Dec 03, 2018 | $12,631 | 0 | 1 |
| ResearchProtocol 0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy Nov 20, 2018 | $11,044 | 0 | 3 |
| Oral Iferoban | $10,750 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Gordon Bernard, Md, MD | Pulmonary Disease | Nashville, TN | $762,000 | $0 |
| Todd Rice, Md, MD | Critical Care Medicine | Nashville, TN | $225,025 | $0 |
| Stephen Southworth, Md, MD | Adult Reconstructive Orthopaedic Surgery | Tupelo, MS | $183,821 | $0 |
| Daniel Sajewski, M.d, M.D | Anesthesiology | Roslyn, NY | $110,568 | $0 |
| Vatsala Sastry, Md, MD | Infectious Disease | Brooksville, FL | $78,868 | $0 |
| Dr. Michael Lew, Md, MD | Anesthesiology | Duarte, CA | $52,649 | $0 |
| Dr. Micah Jacobs, Md, MD | Infectious Disease | Pittsburgh, PA | $43,673 | $0 |
| Dr. Javeed Siddiqui, Md, Mph, MD, MPH | Infectious Disease | Roseville, CA | $41,528 | $0 |
| Mark Chaet, Md, MD | Pediatric Surgery | Orlando, FL | $37,274 | $0 |
| Dino Delaportas, M.d, M.D | Infectious Disease | Bridgeport, WV | $33,433 | $0 |
| Unknown Provider | — | — | $29,310 | $0 |
| Mohamed Erritouni, Md, MD | Internal Medicine | Delray Beach, FL | $27,245 | $0 |
| Dr. Devjit Nayar, Md, MD | Gastroenterology | Hoboken, NJ | $25,201 | $0 |
| Dr. Thuan Le, M.d, M.D | Infectious Disease | Murrieta, CA | $21,606 | $0 |
| Dr. Ali Hassoun, Md, MD | Infectious Disease | Huntsville, AL | $20,791 | $0 |
| Dr. Dhiresh Joshi, M.d, M.D | Infectious Disease | Las Vegas, NV | $17,538 | $0 |
| Sunil George, M.d, M.D | Nephrology | Greenlawn, NY | $16,480 | $0 |
| Brian Metzger, Md, MD | Infectious Disease | Austin, TX | $16,404 | $0 |
| Vipul Desai, Md, MD | Infectious Disease | The Woodlands, TX | $15,322 | $0 |
| Massoud Dezfuli, D.o, D.O | Infectious Disease | Rancho Mirage, CA | $14,880 | $0 |
| Dr. Alan Bulbin, M.d, M.D | Infectious Disease | Greenvale, NY | $14,738 | $0 |
| Biff Palmer, Md, MD | Internal Medicine | Dallas, TX | $14,220 | $0 |
| Mr. Michael Burns, Crna, CRNA | Nurse Anesthetist, Certified Registered | Nashville, TN | $11,865 | $0 |
| Unknown Provider | — | — | $11,799 | $0 |
| Dr. Kerry Cleveland, Md, MD | Infectious Disease | Memphis, TN | $11,236 | $0 |
Ad
Top Products
- KRISTALOSE $520,343
- CALDOLOR $500,946
Associated Products (10)
- KRISTALOSE $520,343
- CALDOLOR $500,946
- Caldolor $419,618
- Vibativ $237,648
- Omeclamox $46,379
- Vaprisol $37,265
- REDITREX $21,113
- Kristalose 10gm $20,825
- Kristalose 20gm $14,348
- Vaprisol Dextrose in Plastic Container $11,118
Payment Categories
- Food & Beverage $673,240
- Consulting $1.2M
- Travel & Lodging $65,035
- Research $4.6M
- Royalties $55,508
About Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals, Inc. has made $7.2M in payments to 11,769 healthcare providers, recorded across 33,535 transactions in the CMS Open Payments database. In 2024, the company paid $867,641. The top product by payment volume is KRISTALOSE ($520,343).
Payments were distributed across 178 medical specialties. The top specialty by payment amount is Pulmonary Disease ($773,809 to 123 doctors).
Payment categories include: Food & Beverage ($673,240), Consulting ($1.2M), Research ($4.6M), Travel & Lodging ($65,035), Royalties ($55,508).
Cumberland Pharmaceuticals, Inc. is associated with 10 products in the CMS Open Payments database, including KRISTALOSE, CALDOLOR, and Caldolor.